Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?

Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

The small cap biotech Instil Bio tries to follow in Summit’s slipstream.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.